Metagenomi(US:MGX)2025-11-12 13:39Financial Position - Metagenomi reported a cash position of $184.1 million as of September 30, 2025, expected to support operations into Q4 2027[9]. - Collaboration revenue for Q3 2025 was $8.7 million, down from $11.5 million in Q3 2024[22]. - The net loss for Q3 2025 was $20.4 million, compared to a net loss of $18.8 million in Q3 2024[22]. Research and Development - R&D expenses for Q3 2025 were $25.3 million, a decrease from $26.3 million in Q3 2024, while G&A expenses were $6.2 million compared to $7.6 million in the same period[9][10]. - The company has prioritized the MGX-001 hemophilia A program, with new preclinical data demonstrating curative FVIII activity in non-human primates[5][3]. - Metagenomi aims to nominate one development candidate from four Wave 1 collaboration targets in 2025 and initiate IND-enabling activities in 2026[7]. - The company is on track to achieve proof-of-concept data for lead secreted protein deficiency targets in 2025[6]. Organizational Changes - The workforce has been reduced by 25% as part of an organizational restructuring to optimize R&D efforts and extend cash runway[1][13]. - Jian Irish has been appointed as CEO, succeeding Brian Thomas, who remains on the Board of Directors[2][4]. Future Plans - Metagenomi plans to submit an IND/CTA for MGX-001 in Q4 2026 following a pre-IND meeting expected in Q4 2025[1].